CA2698569A1 - Tumor grading and cancer prognosis - Google Patents

Tumor grading and cancer prognosis Download PDF

Info

Publication number
CA2698569A1
CA2698569A1 CA2698569A CA2698569A CA2698569A1 CA 2698569 A1 CA2698569 A1 CA 2698569A1 CA 2698569 A CA2698569 A CA 2698569A CA 2698569 A CA2698569 A CA 2698569A CA 2698569 A1 CA2698569 A1 CA 2698569A1
Authority
CA
Canada
Prior art keywords
cancer
mgi
grade
genes
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2698569A
Other languages
English (en)
French (fr)
Inventor
Mark G. Erlander
Xiao-Jun Ma
Dennis Sgroi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Biotheranostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2698569A1 publication Critical patent/CA2698569A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2698569A 2007-09-06 2008-09-06 Tumor grading and cancer prognosis Abandoned CA2698569A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97052907P 2007-09-06 2007-09-06
US60/970,529 2007-09-06
PCT/US2008/075528 WO2009108215A1 (en) 2007-09-06 2008-09-06 Tumor grading and cancer prognosis

Publications (1)

Publication Number Publication Date
CA2698569A1 true CA2698569A1 (en) 2009-09-03

Family

ID=40790735

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2698569A Abandoned CA2698569A1 (en) 2007-09-06 2008-09-06 Tumor grading and cancer prognosis

Country Status (7)

Country Link
US (3) US9447470B2 (show.php)
EP (1) EP2195467B1 (show.php)
JP (2) JP2010538609A (show.php)
CN (1) CN102395682B (show.php)
CA (1) CA2698569A1 (show.php)
ES (1) ES2618353T3 (show.php)
WO (1) WO2009108215A1 (show.php)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
CA2610752A1 (en) * 2005-06-03 2006-12-14 Aviaradx, Inc. Identification of tumors and tissues
WO2010151731A1 (en) * 2009-06-26 2010-12-29 University Of Utah Research Foundation Materials and methods for the identification of drug-resistant cancers and treatment of same
EP2648762B1 (en) * 2010-12-09 2018-02-21 Biotheranostics, Inc. Post-treatment breast cancer prognosis
US20120269418A1 (en) * 2011-04-22 2012-10-25 Ge Global Research Analyzing the expression of biomarkers in cells with clusters
WO2013173756A1 (en) 2012-05-18 2013-11-21 University Of North Dakota A method for quantifying proteins and isoforms thereof
BR112014029300A2 (pt) * 2012-05-22 2017-07-25 British Columbia Cancer Agency Branch genes nano46 e métodos para prever resultado de câncer de mama
WO2013190081A1 (en) * 2012-06-22 2013-12-27 Proyecto De Biomedicina Cima, S.L. Methods and reagents for the prognosis of cancer
WO2015035377A1 (en) * 2013-09-09 2015-03-12 British Columbia Cancer Agency Branch Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy
US20150203921A1 (en) * 2013-09-11 2015-07-23 Biotheranostics, Inc. Predicting breast cancer recurrence
US10253369B2 (en) 2014-05-29 2019-04-09 Biotheranostics, Inc. Predicting likelihood of response to combination therapy
EP3374526A4 (en) 2015-11-13 2019-09-11 Biotheranostics, Inc. INTEGRATION OF TUMOR CHARACTERISTICS WITH A BREAST CANINE INDEX
CN107119055A (zh) * 2017-05-18 2017-09-01 南京中医药大学 分子标志物bub1b基因及其应用
CN110021433B (zh) * 2017-08-30 2023-11-17 中山大学 一种用于精准预测胃肠胰神经内分泌肿瘤患者预后的系统
TW202022124A (zh) * 2018-08-17 2020-06-16 瑞士商赫孚孟拉羅股份公司 用於治療乳癌的診斷及治療方法
CN109706160A (zh) * 2019-02-22 2019-05-03 广西医科大学 重组人蛋白激酶Nek2蛋白表达和纯化方法
KR102405973B1 (ko) 2019-09-20 2022-06-07 고려대학교 산학협력단 유방암 초음파 영상과 유전자 정보를 이용한 유방암 치료법 선택을 위한 정보를 제공하는 방법
KR102508210B1 (ko) * 2020-10-16 2023-03-10 고려대학교 산학협력단 유방암 초음파 영상을 이용한 dna 유전자 정보를 제공하는 방법
CN115029437A (zh) * 2022-04-28 2022-09-09 深圳市陆为生物技术有限公司 检测样本中生物标志物的试剂在制备乳腺癌患者化疗响应评估产品中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
WO2000029044A2 (en) 1998-11-13 2000-05-25 Pro Duct Health, Inc. Devices and methods to identify ductal orifices during nipple aspiration
US20030228575A1 (en) * 2001-01-31 2003-12-11 Yuk Ming Dennis Lo Combination of circulating epstein-barr virus (EBV) DNA in the serum or plasma of patients and a method to assess EBV subtypes for the prediction and detection of epstein-barr virus associated cancers
CA2443627A1 (en) * 2001-05-16 2002-11-21 Novartis Ag Genes expressed in breast cancer as prognostic and therapeutic targets
EP1468110A4 (en) * 2001-06-10 2008-01-30 Irm Llc MOLECULAR SIGNATURES NORMALLY TO THE DEATH LEADING CARCINOME
US20030198972A1 (en) * 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
EP3470535B1 (en) * 2003-06-24 2020-04-01 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
EP3330875B1 (en) * 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
BRPI0414446A (pt) * 2003-09-18 2006-11-14 Genmab As métodos para triar um agente terapêutico, para a supressão da sequência de polinucleotìdeo, para o tratamento de um cáncer não dependente de esteróide, para triar a ligação de um agente especificamente a um polinucleotìdeo e para determinar se um paciente está em risco de desenvolver ou ter um cáncer não dependente de esteróide, composição farmacêutica, usos de um agente terapêutico, de uma molécula anti-sentido ou de uma célula que expressa e/ou contém a molécula anti-sentido, de pelo menos uma das proteìnas de membrana imunogênicas, fragmentos, derivados ou homólogos destas ou de uma célula que contém e/ou que expressa pelo menos uma das proteìnas de membranas imunogênicas ou fragmentos, derivados ou homólogos destas e de um agente ou anticorpo, agente, e, kit para identificar um paciente em risco de desenvolver ou ter cáncer não dependente de esteróide
CA2539107A1 (en) * 2003-09-19 2005-03-31 Arcturus Bioscience, Inc. Predicting breast cancer treatment outcome
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
US7504214B2 (en) 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
US7498693B2 (en) 2004-02-18 2009-03-03 Diversified Technologies, Inc. More compact and higher reliability power source system
CN101356532B (zh) 2005-05-13 2012-08-01 布鲁塞尔自由大学 基于基因的算法型癌症预后
CA2610752A1 (en) * 2005-06-03 2006-12-14 Aviaradx, Inc. Identification of tumors and tissues

Also Published As

Publication number Publication date
US12492432B2 (en) 2025-12-09
EP2195467A1 (en) 2010-06-16
JP2010538609A (ja) 2010-12-16
US9447470B2 (en) 2016-09-20
WO2009108215A1 (en) 2009-09-03
US11021754B2 (en) 2021-06-01
EP2195467B1 (en) 2016-12-14
CN102395682A (zh) 2012-03-28
US20110136680A1 (en) 2011-06-09
US20210371934A1 (en) 2021-12-02
ES2618353T3 (es) 2017-06-21
CN102395682B (zh) 2015-09-30
JP2015057055A (ja) 2015-03-26
US20180291461A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
US12492432B2 (en) Tumor grading and cancer prognosis
US12460265B2 (en) Post-treatment breast cancer prognosis
CN101356532B (zh) 基于基因的算法型癌症预后
EP2304631A1 (en) Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
EP2121988B1 (en) Prostate cancer survival and recurrence
IL276505A (en) Determining recurrence of breast cancer
CN107614696A (zh) 基因表现图谱以及将其应用于乳癌医疗之方法
WO2010121123A1 (en) Methods and gene expression signature for assessing ras pathway activity
US10253369B2 (en) Predicting likelihood of response to combination therapy
US20180051342A1 (en) Prostate cancer survival and recurrence
HK1197803A (en) Post-treatment breast cancer prognosis
AU2014318859A1 (en) Predicting breast cancer recurrence
HK1127413A (en) Gene-based algorithmic cancer prognosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130905

FZDE Discontinued

Effective date: 20171026